These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30871330)

  • 21. Hypolipemic agents for stroke prevention.
    Leys D; Deplanque D; Lucas C; Bordet R
    Clin Exp Hypertens; 2002; 24(7-8):573-94. PubMed ID: 12450233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multivariate analysis for coronary heart disease in heterozygote familial hypercholesterolemia patients.
    Sánchez Muñoz-Torrero JF; Rivas MD; Zamorano J; Joya-Vázquez PP; de Isla LP; Padro T; Mata P; The Safeheart Investigators
    Per Med; 2018 Mar; 15(2):87-92. PubMed ID: 29714125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Heterozygous familial hypercholesterolemia: the first challenge for anti-PCSK9 monoclonal antibodies].
    Zambon A
    G Ital Cardiol (Rome); 2016 Apr; 17(4 Suppl 1):22S-30. PubMed ID: 27312020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients.
    Pérez-Calahorra S; Sánchez-Hernández RM; Plana N; Marco-Benedi V; Pedro-Botet J; Almagro F; Brea A; Ascaso JF; Lahoz C; Civeira F;
    Am J Cardiol; 2017 Mar; 119(5):742-748. PubMed ID: 28081939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two novel mutations in exon 3 and 4 of low density lipoprotein (LDL) receptor gene in patients with heterozygous familial hypercholesterolemia.
    Khan SP; Ghani R; Ahmed KZ; Yaqoob Z
    J Coll Physicians Surg Pak; 2011 Jul; 21(7):403-6. PubMed ID: 21777527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients.
    Béliard S; Millier A; Carreau V; Carrié A; Moulin P; Fredenrich A; Farnier M; Luc G; Rosenbaum D; Toumi M; Bruckert E;
    J Clin Lipidol; 2016; 10(5):1129-1136.e3. PubMed ID: 27678429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study.
    Wadström BN; Wulff AB; Pedersen KM; Jensen GB; Nordestgaard BG
    Eur Heart J; 2022 Sep; 43(34):3258-3269. PubMed ID: 34661640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia.
    Langslet G; Breazna A; Drogari E
    J Clin Lipidol; 2016; 10(5):1153-1162.e3. PubMed ID: 27678432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contemporary Trends in the Management and Outcomes of Patients With Familial Hypercholesterolemia in Canada: A Prospective Observational Study.
    Brunham LR; Cermakova L; Lee T; Priecelova I; Alloul K; de Chantal M; Francis GA; Frohlich J
    Can J Cardiol; 2017 Mar; 33(3):385-392. PubMed ID: 27931859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aortic Calcification Progression in Heterozygote Familial Hypercholesterolemia.
    Al Kindi M; Bélanger AM; Sayegh K; Senouci S; Aljenedil S; Sivakumaran L; Ruel I; Al Rasadi K; Al Waili K; Awan Z; Valenti D; Genest J
    Can J Cardiol; 2017 May; 33(5):658-665. PubMed ID: 28449836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statins and peripheral arterial disease.
    Markel A
    Int Angiol; 2015 Oct; 34(5):416-27. PubMed ID: 25410295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
    Ginsberg HN; Rader DJ; Raal FJ; Guyton JR; Baccara-Dinet MT; Lorenzato C; Pordy R; Stroes E
    Cardiovasc Drugs Ther; 2016 Oct; 30(5):473-483. PubMed ID: 27618825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report.
    Zenti MG; Stefanutti C; Sanga V; Altomari A; Fabris A; Dauriz M; Bonora E
    J Clin Apher; 2018 Aug; 33(4):546-550. PubMed ID: 29638018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aortic Valvular Disease in Elderly Subjects with Heterozygous Familial Hypercholesterolemia: Impact of Lipid-Lowering Therapy.
    Marco-Benedí V; Laclaustra M; Casado-Dominguez JM; Villa-Pobo R; Mateo-Gallego R; Sánchez-Hernández RM; Blanco Nuez M; Ortega-Martínez de Victoria E; Sitges M; Pedro-Botet J; Puzo J; Villarroel T; Civeira F
    J Clin Med; 2019 Dec; 8(12):. PubMed ID: 31847331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and genetic differences between heterozygous familial hypercholesterolemia patients with and without type 2 diabetes.
    Climent E; Pérez-Calahorra S; Benaiges D; Pintó X; Suárez-Tembra M; Plana N; Sánchez-Hernández RM; Valdivielso P; Ascaso JF; Pedro-Botet J
    Rev Esp Cardiol (Engl Ed); 2020 Sep; 73(9):718-724. PubMed ID: 31672559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxidative stress-responsive apoptosis-inducing protein in patients with heterozygous familial hypercholesterolemia.
    Sato K; Yao T; Fujimura T; Murayama K; Okumura K; Hagiwara N; Seko Y
    Heart Vessels; 2021 Dec; 36(12):1923-1932. PubMed ID: 34308503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclooxygenase-2 (COX-2) G-765C is a protective factor for coronary artery disease but not for ischemic stroke: a meta-analysis.
    Li W; Xu J; Wang X; Chen J; Zhang C; Sun K; Hui R
    Atherosclerosis; 2009 Dec; 207(2):492-5. PubMed ID: 19631939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Familial hypercholesterolemia/autosomal dominant hypercholesterolemia: Molecular defects, the LDL-C continuum, and gradients of phenotypic severity.
    Foody JM; Vishwanath R
    J Clin Lipidol; 2016; 10(4):970-986. PubMed ID: 27578130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.
    Kastelein JJ; Hovingh GK; Langslet G; Baccara-Dinet MT; Gipe DA; Chaudhari U; Zhao J; Minini P; Farnier M
    J Clin Lipidol; 2017; 11(1):195-203.e4. PubMed ID: 28391886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.